Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Cardiovascular diseases stories

Nov 9, 2026

FDA approves Bayer's asundexian as first-in-class factor XIa inhibitor for stroke prevention

The FDA approved asundexian (Sunharbo), a novel blood thinner from Bayer, to reduce the risk of recurrent stroke in adults, marking the first approval in the factor XIa inhibitor class.

Nov 9, 2026·6 sources
00
Nov 8, 2026

Semaglutide improves cardiac structure and hemodynamics in heart failure with preserved ejection fraction

Two placebo-controlled trials presented at the 2026 AHA Scientific Sessions found semaglutide significantly improved cardiac structure, function, and pulmonary artery wedge pressure in patients with heart failure with preserved ejection fraction and obesity.

Nov 8, 2026·2 sources
00
Nov 5, 2026

Amgen's Repatha linked to fewer heart attacks versus Zetia in new data

New data from Amgen showed its PCSK9 inhibitor Repatha reduced heart attack risk by approximately 20% more than Zetia (ezetimibe) in patients where statins are insufficient.

Nov 5, 2026·2 sources
00
Nov 2, 2026

Novartis heart drug failure raises questions about genetic cholesterol target

The recent failure of a Novartis experimental heart drug in a large trial has raised questions among cardiologists about the widely held idea that reducing levels of genetically set cholesterol improves cardiovascular outcomes.

Nov 2, 2026·2 sources
00
Nov 1, 2026

Sen. Chris Murphy hospitalized after suffering stroke

Connecticut Senator Chris Murphy, 53, was hospitalized Saturday after experiencing numbness in his arm and suffering a stroke. His office says he is responding well to treatment and expected to make a full recovery.

Nov 1, 2026·6 sources
00
Oct 30, 2026

European researchers develop blood test using ten markers to assess healthy aging and disease risk

Researchers led by Joris Deelen have created a personalized metabolic indicator that uses ten blood markers to provide a detailed snapshot of a patient's metabolism, aimed at promoting healthy aging and reversing the trend of chronic conditions affecting 60% of people over age 65.

Oct 30, 2026·2 sources
00

Blocking microRNA-31-5p interaction reverses heart scarring and atrial fibrillation in study

Researchers at Baylor College of Medicine and University of Oxford found that blocking a specific molecular interaction between microRNA-31-5p and calcitonin receptor reduced atrial fibrosis and abnormal heart rhythms in mouse models and human cells, offering a potential RNA-based therapeutic strategy for atrial fibrillation.

Oct 30, 2026·2 sources
00
Oct 29, 2026

Iron-based MRI contrast agent detects and slows heart scarring in lab-grown tissue

Researchers led by Aitziber L. Cortajarena at CIC biomaGUNE have developed a new iron-based contrast agent for magnetic resonance imaging that can both diagnose and treat cardiac fibrosis. The agent was tested on three-dimensional models of human cardiac tissue using preclinical MRI scanners.

Oct 29, 2026·2 sources
00

Abbott wins FDA approval for Amplatzer Paraclose device to treat heart valve leaks

Abbott received FDA approval for its Amplatzer Paraclose PVL Occluder, the first transcatheter device designed to close paravalvular leaks around surgical replacement heart valves without requiring additional open-heart surgery.

Oct 29, 2026·1 source
00
Oct 28, 2026

Heat waves increase stroke risk in older adults, University of São Paulo study finds

Research conducted in Brazil by University of São Paulo scientists found that each additional day of heat wave exposure in São Paulo is associated with increased acute stroke risk in people aged 65 and older. The study defined a heat wave as at least two consecutive days with maximum temperatures of 33.1°C (92°F) or higher.

Oct 28, 2026·3 sources
00

University of Utah researchers discover heart backup energy system using lactate

Researchers at the University of Utah have identified a backup energy system in the heart that uses the protein MCT1 to import lactate into mitochondria, where it is converted to pyruvate to sustain cardiac function when normal glucose pathways fail. The discovery, demonstrated in mouse hearts, shows this mechanism can prevent stress-induced heart failure.

Oct 28, 2026·2 sources
00
Oct 27, 2026

Scientists create first human endothelial cell atlas mapping how blood vessels age

An international research team led by Laura de Rooij at CeMM Research Center for Molecular Medicine has created the Human Aging Endothelial Cell Atlas, revealing how endothelial cells—the inner linings of blood vessels—change throughout a human lifespan. The atlas provides new insights into how blood vessels age from within.

Oct 27, 2026·2 sources
00

University of Manchester researchers discover blood vessel defect in preeclampsia patients

Researchers at the University of Manchester and Manchester University NHS Foundation Trust have identified a previously hidden defect in the tiny blood vessels of women with preeclampsia, a dangerous pregnancy complication. The discovery, published in Circulation Research, could open the door to new treatments for the condition that threatens both mothers and babies.

Oct 27, 2026·2 sources
00
Oct 26, 2026

Heart drug combination reduces kidney damage in septic shock surgery, major trial finds

A major trial published in JAMA shows that a simple adjustment to drugs given during operations for septic shock could prevent thousands of patients from suffering kidney damage. Scientists from the University of Southampton and Zhejiang University School of Medicine conducted the research.

Oct 26, 2026·2 sources
00

Bayer wins China approval for stroke prevention drug asundexian

China's drug regulator approved Bayer's blood thinner asundexian for stroke prevention, marking the first approval globally for this new class of anticoagulant. The approval followed a priority review and represents a significant boost for Bayer's pharmaceutical pipeline.

Oct 26, 2026·3 sources
00
Oct 22, 2026

Study finds most people carry high genetic risk for three common diseases

University of Exeter researchers have characterized the 'average' human genome for the first time, revealing that most people carry high genetic risk for around three of 28 common conditions, including diabetes, cardiovascular disease, and schizophrenia, though this does not mean they are destined to become ill.

Oct 22, 2026·3 sources
00
Oct 18, 2026

Ultraprocessed food intake linked to silent vascular brain injury, study finds

A cross-sectional study of nearly 9,000 Canadian adults found that higher consumption of ultraprocessed foods was associated with silent vascular brain injury in middle-aged adults without cardiovascular disease, though no apparent effect on cognition was observed. The research also linked ultraprocessed food intake to greater body fat.

Oct 18, 2026·3 sources
00
Sep 26, 2026

Study links ultra-processed foods to increased risk of chronic disease and death

A new analysis published in Family Medicine and Community Health found that greater consumption of ultra-processed foods significantly increases the risk for multiple chronic diseases and death. The findings align with prior research connecting ultra-processed foods to adverse health outcomes including cancer, type 2 diabetes, and cardiovascular disease.

Sep 26, 2026·5 sources
00
Sep 5, 2026

Novartis cholesterol drug pelacarsen fails in major clinical trial

Novartis and Ionis's pelacarsen failed to protect heart health despite lowering Lp(a) levels in a large clinical trial, raising questions about the therapeutic approach and increasing pressure on Novartis's drug pipeline. Shares fell 3.3%.

Sep 5, 2026·2 sources
00
Aug 28, 2026

Cytokinetics reports positive late-stage data for heart drug aficamten

Cytokinetics announced detailed late-stage trial results showing its drug aficamten significantly improved symptoms and exercise capacity in patients with non-obstructive hypertrophic cardiomyopathy, a genetic heart condition with no approved treatments.

Aug 28, 2026·2 sources
00
Aug 5, 2026

Mounjaro Found to Reduce Heart Attack Risk by 33% in Type 2 Diabetes Patients with Heart Disease

A new study shows that tirzepatide (Mounjaro), a GLP-1 receptor agonist drug, reduces heart attack risk by 33% when added to standard care for patients with both type 2 diabetes and existing heart disease. The findings come as worldwide sales of the drug doubled to £13.8 billion in the first half of 2026.

Aug 5, 2026·5 sources
00
May 30, 2026

Mineralys Therapeutics' Experimental Drug Significantly Reduces Blood Pressure in Chronic Kidney Disease Patients

Mineralys Therapeutics presented new data at a major European medical conference showing their experimental pill significantly reduced blood pressure in patients with chronic kidney disease.

May 30, 2026·1 source
00
May 5, 2026

Cytokinetics' Heart Disease Drug Myqorzo Meets Primary Endpoints in Phase 3 Trial for Genetic Heart Condition

Cytokinetics announced its heart disease drug Myqorzo, already approved in one indication, succeeded in meeting twin efficacy goals in a Phase 3 trial for genetic heart disease, potentially boosting future sales.

May 5, 2026·1 source
00
Apr 21, 2026

Frequent Daytime Napping Linked to Early Signs of Health Decline in Older Adults

Frequent, long, or early-day naps in older adults are linked to higher mortality risk and may signal underlying conditions like cardiovascular disease, neurodegeneration, or sleep disorders, suggesting daytime sleep patterns could serve as an early warning sign of declining health.

Apr 21, 2026·4 sources
00
Apr 16, 2026

New Anti-Clotting Drug Asundexian Reduces Stroke Risk Without Increased Bleeding

Large international trial found that investigational drug asundexian reduces stroke risk in people who recently experienced stroke or TIA without added bleeding complications.

Apr 16, 2026·1 source
00
Apr 15, 2026

Loneliness Associated with Higher Risk of Degenerative Heart Valve Disease

Adults who reported feeling lonely had a higher risk of developing degenerative heart valve disease, even after accounting for traditional heart disease risk factors and genetics, according to new research.

Apr 15, 2026·1 source
00

Top claims

  • ▪Sunharbo remains under regulatory review by health authorities in Europe and Japan
  • ▪In the Phase 3 OCEANIC-STROKE trial of 12,327 patients, Sunharbo reduced recurrent ischemic stroke risk by 26% compared to placebo when added to antiplatelet therapy
  • ▪The FDA advised avoiding Sunharbo with strong CYP3A4 and P-glycoprotein inducers, and advised against its use in moderate-to-severe hepatic impairment or atrial fibrillation

Subtopics

Drug Policy, Pricing & Approval10Clinical trials9Drug Approval and Clinical Trials8Pharmaceutical Industry5Biomedical research4Heart health4Longevity & aging4Medical research4Pharma4Biomarkers & bloodwork testing3Cardiovascular aging experts3Chronic disease3Drug development3Molecular biology3Age related cognitive decline2Anticoagulants2Biomedical engineering2Cholesterol management2Clinical trial endpoints2FDA drug approval2Genetic disorders2Genomics2GLP-1 receptor agonists2Lifestyle, Wellness and Nutrition2

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories